2 results
Approved WMOCompleted
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
Approved WMOWill not start
1. To assess the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's disease (AD).2. To assess the pharmacokinetics (PK) of ABBV-8E12 in subjects with early AD.The exploratory objectives of this study are:• To…